These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 18813134)
1. Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Grossman I; Sullivan PF; Walley N; Liu Y; Dawson JR; Gumbs C; Gaedigk A; Leeder JS; McEvoy JP; Weale ME; Goldstein DB Genet Med; 2008 Oct; 10(10):720-9. PubMed ID: 18813134 [TBL] [Abstract][Full Text] [Related]
2. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. Naber D; Lambert M CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194 [TBL] [Abstract][Full Text] [Related]
3. What CATIE found: results from the schizophrenia trial. Swartz MS; Stroup TS; McEvoy JP; Davis SM; Rosenheck RA; Keefe RS; Hsiao JK; Lieberman JA Psychiatr Serv; 2008 May; 59(5):500-6. PubMed ID: 18451005 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK; Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466 [TBL] [Abstract][Full Text] [Related]
5. Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Rosenheck RA; Davis VG; Davis SM; Stroup S; McEvoy J; Swartz M; Lieberman J Schizophr Res; 2009 Aug; 113(1):12-8. PubMed ID: 19545976 [TBL] [Abstract][Full Text] [Related]
6. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. Nasrallah HA J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK; Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435 [TBL] [Abstract][Full Text] [Related]
8. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Addington DE; Mohamed S; Rosenheck RA; Davis SM; Stroup TS; McEvoy JP; Swartz MS; Lieberman JA J Clin Psychiatry; 2011 Jan; 72(1):75-80. PubMed ID: 20868641 [TBL] [Abstract][Full Text] [Related]
9. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial. Ramsey TL; Brennan MD Schizophr Res; 2014 Dec; 160(1-3):73-9. PubMed ID: 25449714 [TBL] [Abstract][Full Text] [Related]
11. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Stroup TS; McEvoy JP; Swartz MS; Byerly MJ; Glick ID; Canive JM; McGee MF; Simpson GM; Stevens MC; Lieberman JA Schizophr Bull; 2003; 29(1):15-31. PubMed ID: 12908658 [TBL] [Abstract][Full Text] [Related]
12. Olanzapine versus other atypical antipsychotics for schizophrenia. Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348 [TBL] [Abstract][Full Text] [Related]
13. What do large scale studies of medication in schizophrenia add to our management strategies? Agius M; Davis A; Gilhooley M; Chapman S; Zaman R Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774 [TBL] [Abstract][Full Text] [Related]
14. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ; Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK; N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203 [TBL] [Abstract][Full Text] [Related]
16. Interpreting the efficacy findings in the CATIE study: what clinicians should know. Meltzer HY; Bobo WV CNS Spectr; 2006 Jul; 11(7 Suppl 7):14-24. PubMed ID: 16816796 [TBL] [Abstract][Full Text] [Related]
17. Are we treating schizophrenia effectively? Understanding the primary outcomes of the CATIE study. Glazer WM; Conley RR; Citrome L CNS Spectr; 2006 Sep; 11(9 Suppl 10):1-13; quiz 14. PubMed ID: 16946697 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Volavka J; Czobor P; Citrome L; Van Dorn RA CNS Spectr; 2014 Oct; 19(5):374-81. PubMed ID: 24284234 [TBL] [Abstract][Full Text] [Related]